

Aktuelle Studien Asklepios Klinik Altona

Kurztitel	RAGNAR	Phase II	second-line
Indikation	verschiedene		
Studientitel	A Phase 2 study of erdafitinib in subjects with advanced solid Tumors and FGFR gene alterations		
Sponsor	Janssen		

Kurztitel	CANFOUR	Phase II	first-line
Indikation	Pankreaskarzinom		
Studientitel	An open-Label, dose escalation followed by dose Expansion, safety and tolerability Trial of CAN04, a fully humanized monoclonal antibody against IL1RAP in subjects with solid malignant tumors.		
Sponsor	Cantargia		

Kurztitel	AIO-TRK-0119 „SPACE“	Phase II	
Indikation	ES-SCLC		
Studientitel	Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide		
Sponsor	AIO		

Kurztitel	MK3475-811	Phase III	first-line
Indikation	Magenkarzinom		
Studientitel	A Phase III randomized, double-blind Trial comparing trastuzumab plus chemotherapy and pembrolizumab or Placebo as first-line Treatment in participants with HER2 positive metastatic gastric or gastroesophageal junction adenocarcinoma		
Sponsor	MSD Sharp & Dohme GmbH		

Kurztitel	MK3475-859	Phase III	first-line
Indikation	Magenkarzinom		
Studientitel	Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma		
Sponsor	MSD Sharp & Dohme GmbH		

Kurztitel	CA209-8HW	Phase III b	first/second-line
Indikation	Mikrosatelliten-Instabilität (MSI-H) oder Mismatch-Repair Defekt (dMMR)		
Studientitel	A Phase 3b randomized clinical Trial of nivolumab alone, nivolumab in combination with ipilimumab or an investigator's choice chemotherapy in participants with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer		
Sponsor	BMS		

Kurztitel	Ipsen IL3 PANC	Phase III	first-line
Indikation	Pankreaskarzinom		
Studientitel	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas.		
Sponsor	Ipsen		

Kurztitel	AIO-KRK-0214	Phase II	first-line/OP
Indikation	Kolorektales Karzinom		
Studientitel	mFOLFOX6 vs mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized Phase II-trial.		
Sponsor	AIO		

	INCB54828-302 FIGHT	III	first-line
Indikation	Cholangiokarzinom		
Studientitel	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)		
Sponsor	Incyte		

Kurztitel	ABX464-401	Phase II/III	n.a.
Indikation	Covid 19		
Studientitel	A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged ≥ 65 and patients aged ≥ 18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).		
Sponsor	Abivax		